| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 191.3 | 177.3 | 163.4 |
| Other income | 9.5 | 24.3 | 7.2 |
| Total income | 200.9 | 201.5 | 170.6 |
| Profit before exceptional items & tax | 29.0 | 47.6 | 28.8 |
| Profit before tax | 29.0 | 47.6 | 28.8 |
| Net profit | 20.4 | 36.2 | 20.0 |
| Operating margin | 14.4% | 23.6% | 16.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +2.00% |
|---|---|
| Net profit, quarter on quarter | -43.60% |
| Revenue, year on year | +17.10% |
| Operating profit, year on year | -9.70% |
| Operating profit, quarter on quarter | -16.30% |
BSE results filing, NSE: LINCOLN. Figures extracted from the filing.
Lincoln Pharmaceuticals Ltd: key numbers
- Share price
- ₹508.00
- Market cap
- ₹1,018 Cr
- Revenue (annual)
- ₹671.0 Cr
- Net profit (annual)
- ₹87.89 Cr
- P/E (TTM)
- 10.5×Sector 46.1×
- Promoter holding
- 49.78%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lincoln Pharmaceuticals Ltd
All →Lincoln Pharmaceuticals Board Meeting Date
Lincoln Pharmaceuticals intimated that its Board meeting is scheduled for 29 Oct 2026 to approve Q1/H1 2026 financial results. Trading window remains closed until 48 hours after results are published.
Lincoln Pharmaceuticals Other Announcement
Lincoln Pharmaceuticals Ltd has filed its quarterly shareholding pattern statement for the period ended September 30, 2026, as required under SEBI regulations.
Lincoln Pharmaceuticals Management Change
Lincoln Pharmaceuticals Ltd announced the resignation of Mr. Pradeep Kumar Yadav, Senior General Manager - Quality Assurance, effective October 17, 2026.
Lincoln Pharmaceuticals Annual General Meeting
Lincoln Pharmaceuticals submitted the minutes and voting results of its 32nd Annual General Meeting held on September 30, 2026. The meeting concluded successfully.
Lincoln Pharmaceuticals Annual General Meeting
Lincoln Pharmaceuticals held its 32nd Annual General Meeting on September 30, 2026, where shareholders considered financial statements, dividends, and director reappointments.
Lincoln Pharmaceuticals Management Change
Lincoln Pharmaceuticals announced the resignation of Mr. Manoj Rai, Sr. General Manager (Head QA), a Senior Management Personnel. He departs effective 24 September 2026 for personal reasons.